Alpha 2.0
Login Register
» Authors » Xiayang Ren

Xiayang Ren

Explore the profile of Xiayang Ren including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 15
Followers 0
Related Specialties
Pharmacology
Allergy & Immunology
Oncology
Top 10 Co-Authors
Yanfeng Wang
Chanjuan Cui
Lei Deng
Wei Cui
Guohui Li
Xiangli Cui
Wenqing Wang
Ying Chen
Siyu Zhang
Lu Li
Published In
Expert Opin Drug Saf
Int J Immunopathol Pharmacol
BMC Cancer
Front Oncol
Eur J Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
Adverse reactions of immune checkpoint inhibitors combined with angiogenesis inhibitors: A pharmacovigilance analysis of drug-drug interactions
Ren X, Deng L, Dong X, Bai Y, Li G, Wang Y
Int J Immunopathol Pharmacol . 2024 Dec; 38:3946320241305390. PMID: 39660594
The combination of immune checkpoint inhibitors (ICIs) and angiogenesis inhibitors (AGIs) is widely used in cancer treatment; however, drug-drug reactions (DDIs) remain unknown. We aimed to identify interaction signals for...
2.
Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions
Ren X, Li L, Chen Y, Cui X, Wan R, Wang Y
BMC Cancer . 2024 Sep; 24(1):1193. PMID: 39334098
Background: Combining immune checkpoint and proton pump inhibitors is widely used in cancer treatment. However, the drug-drug interactions of these substances are currently unknown. This study aimed to explore drug-drug...
3.
Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system
Chen Y, Ren X, Dai Y, Wang Y
Sci Rep . 2024 Sep; 14(1):21386. PMID: 39271716
Antibody-drug conjugates (ADCs) are among the fastest-growing classes of anticancer drugs, making it crucial to evaluate their potential for causing peripheral neuropathy. We analyzed data from the FAERS database (January...
4.
Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database
Hou Y, Ren X, Chen Y, Wang Y
Expert Opin Drug Saf . 2024 Aug; :1-9. PMID: 39137926
Background: Selective RET-specific tyrosine kinase inhibitors (RET-TKIs) treat RET fusion-positive non-small cell lung cancer (NSCLC), but studies on their cardiovascular toxicities are limited. This study aimed to characterize the cardiovascular...
5.
PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system database
Ren X, Sun P, Wang Y
Expert Opin Drug Saf . 2024 Jul; 23(11):1463-1471. PMID: 38967020
Background: Current clinical trial data on PARP inhibitors (PARPis)-related acute renal failure (ARF) are not entirely representative of real-world situations. Therefore, in this study, the US Food and Drug Administration...
6.
Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022)
Ren X, Wang H, Deng L, Wang W, Wang Y
Int Immunopharmacol . 2024 Jun; 136:112301. PMID: 38838553
Introduction: Although immune checkpoint inhibitors (ICIs) combined with angiogenesis inhibitors (AGIs) has become increasingly used for cancers, the impact of combination therapy on immune-related adverse events (irAEs) in real-world settings...
7.
Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database
Ren X, Zhang G, Li G, Wang Y
BMC Cancer . 2024 Jan; 24(1):10. PMID: 38166723
Background: Nervous system toxicity (NST) is one of the most frequent and dangerous side effects of chimeric antigen receptor T-cell (CAR-T) therapy, which is an effective treatment for related tumors...
8.
Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022
Wang Y, Cui C, Deng L, Wang L, Ren X
Front Immunol . 2023 Jun; 14:1127128. PMID: 37292205
Background: Immune checkpoint inhibitors (ICIs) combined with angiogenesis inhibitors (AGIs) have become increasingly available for multiple types of cancers, although the cardiovascular safety profiles of this combination therapy in real-world...
9.
Immune-related interstitial lung disease induced by different immune checkpoint inhibitors regimens: A real-world study from 2014 to 2022 based on FAERS databases
Cui C, Zhang S, Ren X, Cui W, Wang Y
Eur J Pharmacol . 2023 Feb; 946:175561. PMID: 36736527
This study further approaches immune-related interstitial lung disease adverse event in patients undergoing immune checkpoint inhibitor (ICI) monotherapy, ICI plus chemotherapy and ICI plus anti-VEGF therapy in the postmarketing period....
10.
Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database
Ren X, Yan C, Tian L, Cui X
Int J Immunopathol Pharmacol . 2022 Dec; 36:3946320221145520. PMID: 36565299
Objective: The haematopoietic cytopenia (HC) of the cyclin-dependent kinase (CDK)4/6 inhibitors was evaluated using the Food and Drug Administration Adverse Event Reporting System (FAERS). Method: Data from 1 January 2015...